Clinical-stage Biotechnology Company Reveals New Data From Amezalpat Study

Tempest Therapeutics, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker TPST, is poised to release new data from its global randomized Phase 1b/2 combination study involving amezalpat (TPST-1120) in conjunction with atezolizumab and bevacizumab. This study targets the first-line treatment of hepatocellular carcinoma (HCC). The company has scheduled a premarket press release and a webcasted conference call along with a slide presentation for Thursday, June 20, 2024, at 8:30 a.m. ET. $Tempest Therapeutics(TPST.US)$